Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03062280 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
A Phase 3 study, sponsored by Neurocrine UK Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT03062280 is a Phase 3 study that has completed, run by Neurocrine UK Limited. The registered enrollment target is 91 participants.
The verdict
NCT03062280, a Phase 3 study, has completed, sponsored by Neurocrine UK Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
Subjects completing study DIUR-005 and those who have already completed study DIUR-003 will be offered the opportunity either to continue Chronocort® therapy or to switch from their current glucocorticoid therapy to Chronocort® in this open-label study.
Interventions
- DRUG Hydrocortisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2016-08-18 |
| Est. Completion | 2022-07-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03062280
The ClinicalTrials.gov registry entry for NCT03062280 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine UK Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydrocortisone is the first listed.
NCT03062280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03062280 about?
NCT03062280 is a clinical study titled "A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH". Subjects completing study DIUR-005 and those who have already completed study DIUR-003 will be offered the opportunity either to continue Chronocort® therapy or to switch from their current glucocorticoid therapy to Chronocort® in this open-label study.
What is the current status of trial NCT03062280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2016-08-18. Estimated completion is 2022-07-13.
What interventions are being tested in trial NCT03062280?
The interventions under investigation include: Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT03062280?
This trial is sponsored by Neurocrine UK Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.